Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma – pro
The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor.
EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
M.A. Dimopoulos et al, Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma . Engl J Med 2018; 379:1811-1822
Sophia Danhof, Susanne Strifler, Dorothea Hose, Martin Kortüm, Max Bittrich, Jochen Hefner, Hermann Einsele, Stefan Knop, Martin Schreder. (2018) Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy. Journal of Cancer Research and Clinical Oncology72.
David Killock. (2018) Second elotuzumab triplet efficacious in MM. Nature Reviews Clinical Oncology379.